Amplification of chromosomal DNA is thought to be one of the mechanisms activating cancer-related genes in tumors. To identify the most likely target for amplification in the region 19q13.12-q13.2, detected previously in SKN-3 cells by a genome-wide screening of DNA copy-number aberrations in a panel of oral squamous-cell carcinoma (OSCC) cell lines, we determined the extent of the amplicon, analyzed a panel of cell lines for the expression of candidate genes within the amplicon, and then evaluated growth-suppressive effects by knocking down genes of interest. Reported information about the function and/or expression of each gene, remarkable overexpression in SKN-3 cells and relatively frequent overexpression in additional OSCC lines compared with an immortalized normal oral epithelial cell line, and expression level–dependent proliferation-promoting activity led us to conclude that the p21-activated kinase 4 (PAK4) gene was the most likely target. An immunohistochemical analysis of primary tumors from 105 cases of head and neck SCC including 50 cases of OSCC demonstrated the overexpression of PAK4 to be significantly associated with a poorer prognosis. These findings reveal that the PAK4 overexpression through amplification or other mechanisms promotes the proliferation and/or survival of OSCC cells, and that PAK4 might be a good diagnostic and/or therapeutic target. (Cancer Sci 2009; 100: 1908–1916)
Oral cancer, predominantly oral squamous-cell carcinoma (OSCC), is the most common head and neck neoplasm (head and neck SCC, HNSCC), affecting 270 000 people worldwide each year.(1) Despite recent progress in the diagnosis of and therapeutic modalities for OSCC, the prognosis remains unimproved, reflecting the ineffectiveness of current treatment regimens.(1) A more comprehensive understanding of the molecular pathogenesis of OSCC is urgently needed to identify new targets and strategies for treatment, and the ability to recognize early OSCCs and/or pre-malignant lesions may provide insights into the best phase for chemoprevention.(2) Although OSCC is believed to arise through the accumulation of genetic and epigenetic alterations impairing the function of tumor-suppressor genes or provoking the functions of oncogenes,(3,4) the genes associated with oral carcinogenesis either directly or indirectly still remain an enigma.
DNA amplification, one of the mechanisms for activating oncogenes or genes promoting growth, metastasis, or resistance to drugs and radiation, has been found in a broad spectrum of tumors.(5) Several localized amplicons containing known oncogenes, e.g. ERBB2 (17q), MYC (8q24), and MYCN (2p24), have been shown to have clinical significance as diagnostic and prognostic markers and therapeutic targets.(6) Recently advanced genomic screening strategies for copy-number aberrations (CNAs), including array-based comparative genomic hybridization (array-CGH), have revealed various novel amplified regions, which may contain as yet uncharacterized driver oncogenes, with greater accuracy and a higher spatial resolution than conventional CGH.(7,8) During our previous screening of CNAs in OSCC by array-CGH using in-house bacterial artificial chromosome (BAC)-based arrays against a panel of OSCC cell lines, we identified several remarkably novel amplified regions.(9)
In this study, we focused on a 2.5-Mb-amplicon at 19q13.12-13.2, a novel amplified region detected in the OSCC cell line SKN-3.(9) Although similar amplicons have been observed in other types of tumors, including pancreatic, ovarian, and breast cancers,(10–12) 19q13.12-13.2 is one of the smallest and is unlikely to contain AKT2, the most likely target of amplification at 19q13 reported to date. Here, we present the results of a comprehensive evaluation of the 19q13.12-13.2 amplicon in OSCC cell lines, including detailed analyses of copy-numbers and expression levels as well as loss-of-function screening using synthetic siRNA technology. Through this approach, we identified PAK4, encoding a protein belonging to the group-II p21 protein (Cdc42/Rac)-activated kinase (PAK) family of serine/threonine kinases with significant roles in many fundamental cellular functions and the development of cancer and metastasis,(13) as one possible target for amplification in SKN-3 cells.
Materials and Methods
Cell lines and tissue samples. A total of 22 OSCC cell lines (Ca9-22, HO-1-u-1, HO-1-N-1, HOC-313, HOC-815, HSC-2, HSC-3, HSC-4, HSC-5, HSC-6, HSC-7, KON, KOSC-2, KOSC-3, NA, OM-1, OM-2, Sa3, SAS, SKN-3, TSU, and ZA), which were established from surgically resected tumors in Tokyo Medical and Dental University or purchased from the Japanese Collection of Research Bioresources (Osaka, Japan) and maintained in appropriate media supplemented with 10% FBS, penicillin (100 units/mL), and streptomycin (100 µg/mL), were used for this study. The immortalized normal oral epithelial cell-derived cell line, RT7, kindly provided by Dr Nobuyuki Kamata (Hiroshima University, Hiroshima, Japan), was maintained in keratinocyte serum-free medium containing epidermal growth factor and bovine pituitary extract (Invitrogen, Carlsbad, CA, USA).
Surgically resected specimens used for the immunohistochemical analysis were obtained from 105 patients who had undergone curative resection of HNSCC, excluding the larynx, at the National Defense Medical College Hospital during the period from 1989 to 2000 with written consent from the parents of each patient in the formal style and after approval by the local ethics committee. The primary locus of tumors was the oral cavity in 50 cases, oropharynx in 13, and hypopharynx in 42. Hospital records of clinical and survival data were available for all patients. Clinical and pathologic examinations were performed according to the general rules for clinical studies on head and neck cancer.(14) Disease stage was defined in accordance with the TNM classification.(15) Patient characteristics are listed in Table 1. The median follow-up period for the surviving patients with HNSCCs was 48 months (ranging from 1 to 134.3 months).
Table 1. Association between clinicopathological factors and PAK4 immunoreactivity in primary HNSCC
Note: Statistically significant values are in boldface type.
PAK4 expression was evaluated by immunohistochemical staining as described in ‘Materials and Methods’.
P-values are from χ2 or Fisher's exact tests, and were statistically significant when <0.05 (two-sided).
HNSCC, head and neck squamous-cell carcinoma.
Fluorescence in situ hybridization (FISH). Metaphase chromosomes were prepared from normal male lymphocytes and from each OSCC cell line. FISH analyses were performed as described previously,(14) using BACs as probes.
High-density oligonucleotide array-CGH. A genome-wide analysis of CNAs was performed using the Human Genome CGH Microarray Kit 244K (Agilent Technologies, Santa Clara, CA, USA) according to the directions provided by the manufacturer. The hybridized arrays were scanned using an Agilent scanner (Agilent Technologies). The CGH Analytics program version 3.4.40 (Agilent Technologies) was used to export the array CGH data for usage in other analytical programs.
Quantitative real-time genomic PCR and RT-PCR. Quantitative real-time PCR experiments were performed with an ABI Prism 7900 sequence-detection system (Applied Biosystems, Foster City, CA, USA) as described previously(16) using CYBR Green or with an ABI PRISM 7500 sequence detection System (Applied Biosystems) using TaqMan Gene Expression Assays (Applied Biosystems) according to the manufacturer's instructions. The genomic copy-number of a gene of interest in each sample was normalized by dividing it by the corresponding internal control (COL7A1) value, and recording as a copy-number ratio. mRNA expression levels of genes of interest were normalized against a housekeeping gene, ACTB, as an internal control to collect the relative expression data. Each assay was performed in triplicate for each sample. Primer sequences designed by ourselves are shown in Supporting Table S1.
Western blotting. The anti-PAK4 antibody was purchased from Cell Signaling Technology (Beverly, MA, USA), anti-FLAG tag and anti-β-actin antibodies from Sigma (St. Louis, MO, US), and anti-p21 antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cells were lysed, and lysates were analyzed as described elsewhere.(9)
Loss-of-function by siRNA and cell proliferation analysis. Loss of function screening was done using siRNAs purchased from Santa Cruz Biotechnology (PAK4-siRNA, sc-39060; PSMC4-siRNA, sc-43851; and MAP3K10-siRNA, sc-39111). A control siRNA for the firefly luciferase gene (CGUACGCGGAAUACUUCGA, Luc-siRNA) was synthesized by Sigma. Each siRNA (10 nM) was transfected into cells using Lipofectamine RNAiMAX (Invitrogen). The knockdown of target genes was confirmed by quantitative real-time RT-PCR and/or western blotting. Numbers of viable cells were assessed 24–72 h after transfection using a colorimetric water-soluble tetrazolium salt (WST) assay (Cell counting kit-8; Dojindo, Kumamoto, Japan).(9) The cell cycle was evaluated 72 h after transfection by FACS as described.(9)
Colony-formation assay. Plasmids expressing FLAG-tagged wild-type PAK4 (pCMV-3Tag1A-PAK4WT) and constitutive active (CA) and kinase inactive (KI) mutants of PAK4 (pCMV-3Tag1A-PAK4CA and pCMV-3Tag1A-PAK4KI, respectively) were obtained by cloning the full coding sequences for wild-type PAK4 and the CA and KI mutant forms, in which serine 474 and lysines 350/351were mutagenized to glutamate and alanines, respectively,(17) in-frame into the vector pCMV-3Tag1A (Stratagene, La Jolla, CA, USA) along with the FLAG epitope. Each construct or the empty vector was introduced into cells as described previously.(9) The expression of PAK4 protein in transfected cells was confirmed by western blotting. After 3 weeks of incubation with appropriate concentrations of G418, cells were fixed with 70% ethanol and stained with crystal violet.
Mutation analysis. We looked for mutations in PAK4 by means of direct sequencing, using primers designed for genomic sequences around exons encoding the protein-binding domain, catalytic domain, and activating domain of the PAK4 (exons 4, 6, and 9; Supporting Table S1).
Immunohistochemistry. Indirect immunohistochemistry was done with formalin-fixed, paraffin-embedded tissue sections. Antigens were retrieved by microwave pretreatment in 5N-NaOH buffer for 10 min at 95°C. After blocking in hydrogen peroxide and in 2% normal swine serum, the slides were incubated with an anti-PAK4 antibody (1:100 dilution) overnight at 4°C and then reacted with a Histofine simple stain, MAX PO(G) (Nichirei, Tokyo, Japan). Antigen-antibody reactions were visualized with 0.2% diaminobenzidine tetrahydrochloride and hydrogen peroxide. The slides were counterstained with Mayer's hematoxylin. Formalin-fixed paraffin-embedded SKN-3 cells overexpressing PAK4 mRNA and HSC-7 and SAS cells expressing low levels of PAK4 mRNA were used as positive and negative controls, respectively. The specificity of the antibody was also verified by western blotting. The percentage of the total cell population that expressed PAK4 was evaluated for each case at ×200 magnification. Expression of PAK4 was graded as either positive (≥10% of tumor cell cytoplasm showing immunopositivity) or negative (<10% of tumor cell cytoplasm showing immunopositivity or no staining).
Statistical analysis. Differences between subgroups were tested with the Mann–Whitney U-test. For multiple group comparisons, the one-way anova, followed by Scheffé's post-hoc test, was used. Correlations between PAK4 expression in primary tumors and the clinicopathologic variables pertaining to the corresponding patients were analyzed for statistical significance with the χ2 or Fisher's exact tests. For the analysis of survival, Kaplan–Meier survival curves were constructed for groups based on univariate predictors and differences between the groups were tested with the log-rank test. Multivariate survival analysis was performed using the likelihood ratio test of the Cox proportional-hazards model. Differences were assessed with a two-sided test and considered significant at the P < 0.05 level.
Detailed mapping of the 19q13.12-13.2 amplicon in SKN-3 cells. Using high resolution array-CGH with in-house BAC array, we recently found the region 19q13.12-13.2 to be amplified in one of 18 OSCC cell lines, SKN-3.(9) To map this region in detail, we first performed FISH using 14 sequential BAC clones (RP11-44B13, 115H16, 587I9, 91H20, 140E1, 118P21, 446K10, 787F3, 256O9, 841P21, 343J4, 67A5, 246P10, and 384E6; Fig. 1a) as probes distributing across approximately 3.5 Mb and found remarkable amplification with a homogenously staining region (HSR), on the metaphase chromosomes of SKN-3 cells (Fig. 1a,b). This amplicon is bounded by two BACs, RP11-587I9 and RP11-67A5, whereas three BACs, namely RP11-44B13, RP11-115H16, and RP11-384E6, showed lower copy-number gain comparatively (Fig. 1b and data not shown), helping us to map the amplicon to a 2.5-Mb region (Fig. 1a). Since the oncogene AKT2, a putative and well-characterized target for amplification within 19q13.12-13.2 in other tumors,(10–12) is located at the edge of this amplicon in SKN-3 cells (Fig. 1a,b), we examined whether AKT2 is really included in this amplicon as a potential driver gene. High-density oligonucleotide array-CGH and quantitative genomic PCR analyses demonstrated that most but not the entire AKT2 gene was included within the amplicon (Fig. 1c,d). This result was confirmed by the relatively low level of AKT2 mRNA in SKN-3 cells compared with other OSCC cell lines without the19q13.12-13.2 amplicon (Supporting Fig. S1). Conversely, the defined 19q13.12-13.2 amplicon in SKN-3 contains 66 transcripts (Supporting Table S2), including 49 known genes and 17 possible transcripts encoding hypothetical or predicted proteins, between ZNF573 and CNTD2 based on the human genome databases (http://www.ncbi.nlm.nih.gov/ and http://genome.ucsc.edu/), prompting us to explore novel targets for amplification other than the AKT2 gene.
Based upon the hypothesis that putative targets for amplification could be highly expressed in cells with high-level amplification and also show increased expression in cancer cells compared with cells from normal tissue,(8) we next performed quantitative RT-PCR analyses of all 31 selected genes to compare the mRNA levels in a panel of 22 OSCC cell lines within those in the control RT7 cell line (Fig. 2b and Supporting Fig. S1). In the quantitative analysis, we found three patterns (patterns A, B, and C) of expression among the 31 genes (Fig. 2b, Supporting Fig. S1, and Supporting Table S2). We paid particular attention to 17 genes in patterns A and B, which showed high mRNA levels in SKN-3 cells along with other OSCC lines to some extent compared with RT7 cells, whereas we excluded 14 genes which did not fulfill this criterion (pattern C in Fig. 2b and Supporting Fig. S1). Among these 17 genes, PAK4, PSMC4, and MAP3K10, were overexpressed frequently in OSCC cell lines having no amplification (>5/21 cell lines) and expressed at the highest levels in the amplified SKN-3 cells (pattern A in Fig. 2b). The expression pattern of PAK4 protein, for which a specific antibody is available for western blotting, correlated with that of the mRNA in a panel of OSCC lines (Fig. 2c). On the other hand, 14 genes were overexpressed in SKN-3 cells, but not in most of the other OSCC cell lines, compared with RT7 cells (pattern B in Fig. 2b and Supporting Fig. S1), suggesting those genes to be given less priority in our selection of targets.
Based on the series of in silico and experimental analyses described above, we chose three known genes, PAK4, PSMC4, and MAP3K10, as candidate targets for 19q13.12-13.2 amplification in the SKN-3 cell line.
Effect of knockdown of candidate targets on proliferation of OSCC cells. To identify which of the amplified targets are functionally important in OSCC, we silenced the expression of each gene using siRNA in OSCC lines. We first evaluated the effect of siRNA for each gene on cell viability in SKN-3 cells with high-level amplification/overexpression of those genes. Treatment with the gene-specific siRNA successfully down-regulated the mRNA expression of each gene compared with control siRNA (Luc-siRNA, Fig. 3a).
Down-regulation of PAK4, PSMC4, and MAP3K10 expression resulted in a significant reduction in the viability of SKN-3 cells (Fig. 3a). On the other hand, down-regulation of PAK4 expression did not remarkably reduce proliferation in HSC-7 cells, one of the cell lines showing a lower expression level of this gene, whereas down-regulation of PSMC4 and MAP3K10 expression significantly suppressed the proliferation of HSC-7 cells (Fig. 3b). As in SKN-3 cells, in addition, downregulation of PAK4 expression in NA cells, which show relatively high levels of PAK4 expression without amplification, reduced proliferation (Supporting Fig. S2), suggesting that PAK4, but not PSMC4 or MAP3K10, have a proliferation-promoting effect in an expression level–dependent manner in OSCC cells.
We further characterized the proliferation-inhibiting effect of the knockdown of PAK4 in SKN-3 cells. In a FACS analysis of SKN-3, treatment with siRNA for PAK4 resulted in an accumulation of cells in G0-G1 phase compared with control Luc-siRNA-treated counterparts (Fig. 3c). Consistent with the result of the FACS analysis, p21 protein expression was highly induced after treatment with PAK4-siRNA compared with control Luc-siRNA (Fig. 3c).
To confirm the proliferation-promoting effect of the ectopic overexpression of PAK4 in OSCC cells and clarify whether it depends on the kinase activity of PAK4, we carried out a colony-formation assay by transfecting the expression construct of the WT, CA mutant (S474E), or KI mutant (K350A/K351A) of PAK4 into cells having relatively low levels of PAK4. Ectopic expression of wild-type and mutant PAK4 with a FLAG-tag in these cell lines was verified by western blotting using an epitope tag-specific antibody (Fig. 3d). The KI mutant showed lower PAK4 levels in both cell lines, although no difference in the mRNA expression of ectopically expressed PAK4 was detected among constructs by RT-PCR (data not shown). WT PAK4 and the CA mutant produced remarkably more colonies than did the empty plasmid and KI-mutant form of PAK4 in both cell lines (Fig. 3d).
In an analysis in a panel of OSCC cell lines, no mutation was detected within sequences around exons encoding the protein-binding domain, catalytic domain, and activating domain of the PAK4 (data not shown).
Clinicopathological association of PAK4 overexpression in primary HNSCCs. To clarify the clinicopathological significance of PAK4 protein levels in primary HNSCCs including OSCCs, we evaluated the expression of PAK4 protein by immunohistochemistry in 105 primary tumors, including 50 OSCCs and 55 oropharyngeal or hypopharyngeal SCCs.
To confirm the specificity of the immunoreactivity of the anti-PAK4 antibody, we first stained SKN-3 cells (Fig. 4a) as well as HSC-7 and SAS cells (Fig. 4b) as positive and negative controls, respectively. Consistent with the results of RT-PCR and western blotting, strong PAK4 immunoreactivity was observed in SKN-3 cells, whereas weak or almost no immunoreactivity was detected in HSC-7 and SAS cells.
In primary tissues, normal oral and pharyngeal squamous epithelia showed almost no PAK4 immunoreactivity (Fig. 4c and data not shown). On the other hand, immunoreactivity was observed in 70 of 105 primary HNSCCs. In all of the PAK4-positive cases, the immunoreactivity was detected in the cytoplasm of cancer cells. Notably, higher levels of PAK4 protein in primary HNSCCs were frequently observed at the invasive front of the tumors (Fig. 4d) or at the center of the tumor mass (Fig. 4e), indicating potential roles in the progression of tumor cell proliferation or in tumor cell survival, respectively. Among various clinicopathological characteristics (Table 1), PAK4 expression status was significantly associated with category T of the TNM classification: HNSCCs lack PAK4 expression in localized cases (T1 and T2), but exhibit frequent PAK4 expression in diffuse cases (T3 and T4; P = 0.0112, χ2-test). However, the PAK4 protein expression in each tumor was not associated with other characteristics including the age and gender of patients, differentiation status, category N, category M, stage in the TNM classification, or location of tumors. Kaplan–Meier survival estimates showed that PAK4 immunoreactivity in tumor cells was significantly associated with a worse overall survival in all cases (P = 0.0164, log-rank test; Fig. 4f). The prognostic capability of PAK4 was further compared with clinicopathological variables, such as age, differentiation status, and tumor stage using the Cox proportional hazard regression model (Table 2). Multivariate analysis using a stepwise Cox regression procedure revealed that the PAK4 expression status and tumor stage were identified as independently selected predictive factors for overall survival in both forward and backward procedures (P = 0.024 and 0.006, respectively).
Table 2. Cox proportional hazard regression analysis for overall survival
In a previous study using an in-house BAC array, we identified several remarkable changes including amplifications and homozygous deletions in OSCC cell lines.(9) In this study, we focused on one amplified region within 19q13.12-13.2. Amplification of 19q13 has been reported in various tumors including OSCC.(4) Although many possible targets for amplification in this region, such as AKT2, MLL4, CCNE1, SERTAD1, DYRK1B, PAF1, IXL, and ACTN4,(10,18–24) have been reported in various tumors, potential targets in OSCC remain unknown. In this study, we identified PAK4 as a novel target for amplification within 19q13.12-13.2 in OSCC, because (a) increased expression of PAK4 was observed in an OSCC cell line with remarkable amplification of this region (SKN-3) as well as in OSCC lines without amplification; (b) knockdown of PAK4 expression inhibited cell proliferation in an expression level–dependent manner and ectopic overexpression of PAK4 induced cell proliferation; and (c) PAK4 protein overexpression was frequently observed in primary tumors from cases of HNSCC, including OSCC, and correlated with a worse overall survival rate.
Among previously reported targets of amplification at 19q13,(10,18–24)AKT2, MLL4, CCNE1, and SERTAD1 were not included within the 2.5-Mb amplicon detected in SKN-3 cells, indicating that other genes contribute to the pathogenesis of at least some OSCCs. Indeed, our expression analysis demonstrated a low mRNA level of AKT2 in a panel of OSCC lines compared with the normal oral epithelia-derived cell line. Among DYRK1B, PAF1, IXL, and ACTN4 located within the 19q13.12-13.2 amplicon of the SKN-3 cell line, DYRK1B mRNA was not expressed in SKN-3 cells or other OSCC cell lines (Supporting Table S2), and PAF1, IXL, and ACTN4 mRNAs were infrequently overexpressed in OSCC cell lines other than SKN-3 (Fig. 2), suggesting that they are also likely to be excluded as potential candidates for tumor-promoting genes activated in OSCC. Taken together, none of the eight reported genes around 19q13.12-13.2 was included among possible targets for amplification in OSCC.
Among 63 transcripts located within the 2.5-Mb amplicon in the SKN-3 cell line, we chose three genes as possible targets for amplification in OSCC through our systematic approach using public databases as well as expression analyses. Among the three candidates, knockdown of MAP3K10 and PSMC4 inhibited cell proliferation regardless of their expression level in OSCC cell lines, whereas knockdown of PAK4 inhibited cell proliferation in an expression level–dependent manner, suggesting that a recently reported widespread and important phenomenon, termed ‘oncogene addiction’,(25) is applicable to PAK4 in OSCC. After knockdown of PAK4, G1 arrest with an increase in p21 expression was observed in the SKN-3 cell line, suggesting overexpressed PAK4 to promote the proliferation of OSCC cells at least partly by accelerating G1-S transition. In the immunohistochemical analysis of primary HNSCCs, a higher level of PAK4 protein was sometimes observed at the invasive front of the tumors, indicating potential roles in tumor cell proliferation. Combined with the correlation between PAK4 immunoreactivity and a poorer overall survival rate in HNSCC even after stratification with other clinicopathological factors by multivariate analysis, the findings suggest that the proliferation-promoting effect of PAK4 is critical in some lineages of HNSCC even in the earlier stage and that PAK4 expression status may be a prognosticator in cases of HNSCC, although further study using an independent cohort will be needed to test this hypothesis.
PAK4 is a member of the group II PAK serine/threonine kinases originally identified as a protein that promotes filopodial development in response to activated Cdc42.(26,27) PAK4 is highly expressed during embryogenesis but expressed at low levels in most adult tissues,(28) and PAK4 mRNA levels are increased in a wide range of cancer cell lines and primary tumors.(29,30) Those findings suggest that high levels of PAK4, which most likely plays a critical role in the rapid cell proliferation in embryogenesis, may no longer be needed in adult tissues, and improperly expressed or activated PAK4 may promote cell survival, uncontrolled proliferation, and tumorigenesis.(29,30) Indeed, it was reported that PAK4 plays a vital role in Ras-driven, anchorage-independent cell proliferation, a hallmark of oncogenesis.(17) PAK4 was also reported to phosphorylate Raf1 and activates the ERK pathway downstream of Raf, thus playing an additional role in the regulation of cell proliferation and differentiation that is under the control of ERK/MAPK signaling,(31) although our preliminary experiment detected no alteration in the level of activated ERK (data not shown). Overexpression of wild-type or activated PAK4 protects cells from apoptosis induced by UV irradiation or serum withdrawal.(32) In addition, overexpression of PAK4 was shown to lead to the formation of tumors in athymic mice in vivo, whereas deletion of PAK4 inhibited tumorigenesis.(30) However, it was unknown whether overexpressed wild-type or mutated PAK4 directly or indirectly promotes cell proliferation in human cancer. Our results showing that (a) no mutation was detected within the coding sequence with the functional motif of PAK4 in OSCC cell lines, although its proliferation-promoting activity seems to depend on the kinase activity; (b) p21 protein levels were increased after knockdown of PAK4; and (c) frequently observed PAK4 immunoreactivity in primary HNSCCs correlated with a poor prognosis, together with previous reports, suggest that the overexpression of wild-type PAK4 through various mechanisms, including amplification, has the potential to produce conditions favorable for oncogenic transformation through its kinase activity–dependent ability to promote uncontrolled cell proliferation and/or survival. Although PAKs including PAK4 provide compelling evidence for targeting due to their implications in cancer, availability of crystal structures, unique movements of the catalytic motifs, and inhibitor profiling, no specific inhibitor for group-II PAKs has been approved in drug development.(13,27) Development of a PAK4-specific inhibitor will provide new avenues for understanding the physiological and pathophysiological functions as well as an opportunity for PAK4-targeted anticancer therapy.
In summary, our detailed characterization of the 19q13.12-13.2 amplicon detected in an OSCC cell line and sequential analyses of genes within the amplicon revealed that PAK4 is a novel target for amplification/activation. Since knockdown of PAK4 inhibited proliferation in OSCC cells overexpressing this gene and expression status was correlated with tumor size and overall survival in primary cases of HNSCC including OSCC, PAK4 may play a critical role in the proliferation and survival of at least a subset of HNSCCs, and thereby may be a novel prognosticator as well as an attractive therapeutic target. Finally, this study shows that the combination of copy-number and expression analyses together with targeted siRNA screening provides an efficient approach for the identification of novel putative amplification targets, which are correlated with the pathogenesis of human cancer.
This study was supported in part by grants-in-aid for Scientific Research and Scientific Research on Priority Areas, and a grant for the Global Center of Excellence (GCOE) Program, ‘International Research Center for Molecular Science in Tooth and Bone Diseases’, from the Ministry of Education, Culture, Sports, Science, and Technology of Japan; and a grant from the New Energy and Industrial Technology Development Organization (NEDO). We are grateful to Dr Nobuyuki Kamata (Hiroshima University, Hiroshima, Japan) for providing the RT7 cell line, and Ayako Takahashi and Rumi Mori for technical assistance.